Immunological long-term follow-up of neuroblastoma stage IV patients after anti-GD2 CH14.18 antibody treatment.

被引：0
|
作者：
Kayser, Simone
Icheva, Vanya
Stevanovic, Stefan
Siebert, Nikolai
Feucht, Judith
Lode, Holger N.
Handgretinger, Rupert
Feuchtinger, Tobias
机构：
[1] Univ Childrens Hosp, Tubingen, Germany
[2] Univ Tubingen, Dept Immunol, Inst Cell Biol, Tubingen, Germany
[3] Univ Med Greifswald, Greifswald, Germany
[4] Ernst Moritz Arndt Univ Greifswald, Univ Med Ctr, Greifswald, Germany
[5] Univ Munich, Dr von Haunersches Kinderspital, Dept Pediat Hematol Oncol, Munich, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.3029
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3029
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO
    Mueller, Ina
    Ehlert, Karoline
    Endres, Stefanie
    Pill, Lena
    Siebert, Nikolai
    Kietz, Silke
    Brock, Penelope
    Garaventa, Alberto
    Valteau-Couanet, Dominique
    Janzek, Evelyne
    Hosten, Norbert
    Zinke, Andreas
    Barthlen, Winfried
    Varol, Emine
    Loibner, Hans
    Ladenstein, Ruth
    Lode, Holger N.
    MABS, 2018, 10 (01) : 55 - 61
  • [2] Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma
    Ami V. Desai
    Elizabeth Fox
    L. Mary Smith
    Allison Pecha Lim
    John M. Maris
    Frank M. Balis
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 1047 - 1055
  • [3] Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma
    Desai, Ami V.
    Fox, Elizabeth
    Smith, L. Mary
    Lim, Allison Pecha
    Maris, John M.
    Balis, Frank M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (05) : 1047 - 1055
  • [4] Inflammatory response and treatment tolerance of long-term infusion of the anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in patients with high-risk neuroblastoma
    Ceylan, Kiraz
    Jahns, Luciana J.
    Lode, Bjoern N.
    Ehlert, Karoline
    Kietz, Silke
    Troschke-Meurer, Sascha
    Siebert, Nikolai
    Lode, Holger N.
    PEDIATRIC BLOOD & CANCER, 2018, 65 (06)
  • [5] Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab
    Siebert, Nikolai
    Seidel, Diana
    Eger, Christin
    Brackrock, Diana
    Reker, Daniel
    Schmidt, Manuela
    Lode, Holger N.
    JOURNAL OF IMMUNOLOGICAL METHODS, 2013, 398 : 51 - 59
  • [6] Pharmacokinetics (PK) of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma.
    Desai, Ami Vijay
    Fox, Elizabeth
    DiSipio, Theresa C.
    Smith, L. Mary
    Lim, Allison
    Maris, John M.
    Balis, Frank M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] Functional Bioassays for Immune Monitoring of High-Risk Neuroblastoma Patients Treated with ch14.18/CHO Anti-GD2 Antibody
    Siebert, Nikolai
    Seidel, Diana
    Eger, Christin
    Juettner, Madlen
    Lode, Holger N.
    PLOS ONE, 2014, 9 (09):
  • [8] Immune activation and clinical responses following long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in high-risk neuroblastoma patients.
    Lode, Holger N.
    Jensen, Christian
    Endres, Stefanie
    Pill, Lena
    Siebert, Nikolai
    Kietz, Silke
    Ehlert, Karoline
    Brock, Penelope
    Valteau-Couanet, Dominique
    Janzek, Evelyne
    Loibner, Hans
    Ladenstein, Ruth L.
    Mueller, Ina
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Immune activation, clinical response and survival following long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in high-risk neuroblastoma patients
    Lode, Holger
    Jensen, Christian
    Siebert, Nikolai
    Kietz, Silke
    Ehlert, Karoline
    Mueller, Ina
    Ladenstein, Ruth
    Janzek, Evelyne
    Loibner, Hans
    CANCER RESEARCH, 2014, 74 (19)
  • [10] Phase II clinical trial with long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 (IL2) in patients with high risk neuroblastoma.
    Lode, Holger N.
    Valteau-Couanet, Dominique
    Troschke-Meurer, Sascha
    Manzitti, Carla
    Gray, Juliet
    Castel, Victoria
    Yaniv, Isaac
    Loibner, Hans
    Siebert, Nikolai
    Glogova, Evgenia
    Poetschger, Ulrike
    Ladenstein, Ruth
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345